Study Participants Wanted
Note: Only studies being conducted by the UMass Department of Psychiatry will be listed here. No other entries accepted.
Members of the department wishing to submit information like this should use the format below, include a subject line of “Study Participants Wanted,” and email it to email@example.com.
Drinking Behaviors Study
This is a 3 session study (3 total visits over the course of 3 weeks) which looks at drinking behavior and the factors that influence drinking behavior. You will be compensated (paid) for your participation.
You may be eligible to participate if:
- You are 18 years or older
- Have consumed 5 or more alcoholic drinks in a single day (Men) or 4 or more standard drinks in a single day (women) within the last year.
If interested, please call 833-813-8447. All calls are confidential. We can also be contacted via email: firstname.lastname@example.org
IRB Docket #: H00011382
The Substance Use Study
Have you or someone you know been diagnosed with Schizophrenia or Schizoaffective Disorder?
Do you or that person also use alcohol, marijuana, or any other drugs?
If so, you or someone you know may be eligible to participate in a research study conducted at UMass Medical School.
The purpose of this study is to see whether brexpiprazole, an investigational drug, can help reduce substance use in individuals diagnosed with schizophrenia or schizoaffective disorders
Your participation in the study will last 12 weeks, and you will be compensated for your time.
If you are interested and would like more information, please call 508-856-MIND (6463) or email MIND@umassmed.edu.
Funding Source: Otsuka Pharmaceuticals
IRB Docket # H00014611
The Treatment-Resistant Study
Are you above the age of 18, and diagnosed with schizophrenia?
If so, you may be eligible to participate in a research study conducted at UMass Medical School
The purpose of this study is to see whether Lu AF35700, an experimental drug, is safe and effective for the possible treatment of treatment-resistant schizophrenia.
You will be compensated for your time. If you are interested and would like more information,
please call 508-856-MIND (6463) or email MIND@umassmed.edu
Funding Source: H. Lundbeck A/S
IRB Docket # H00014572
Outpatient Couple Therapy for Service Members and Veterans with Alcohol-Related Concerns
The Alcohol Behavioral Couple Therapy Military treatment research program is specifically designed to help service members or veterans and their partners to learn skills that will help to reduce drinking and to improve relationship functioning.
The program will include a thorough assessment, 15 weekly outpatient sessions with a spouse, partner or family member (free of charge), and a follow-up session. Compensation will be provided for the intake and follow-up sessions.
Below are the major inclusion criteria:
- Be a service member or veteran of the U.S. Military (all branches welcome including National Guard and Reserves)
- Have a drinking habit you want to change
- Be 18 or older
- Have a significant other who can attend sessions with you (spouse, dating partner, family member)
For more information, please contact Emily Starratt (508-856-8745) or Dr. Beth Epstein (732-995-7315).
A Psychotic Disorders Program Research Study
Exenatide weekly injection as an adjunctive treatment in patients with schizophrenia
Have you been diagnosed with Schizophrenia or Schizoaffective disorder? Are you interested in helping us learn if a drug called Exenatide may improve your memory and thinking?
If so, you may be eligible to participate in a research study at UMass Medical School. Studies suggest that Exenatide (an FDA-approved drug) can reduce inflammation, which may protect the brain and improve memory and thinking in individuals with schizophrenia or schizoaffective disorder. Your participation in the study will last 24 weeks (6 months).
You will be compensated (paid) for your time. For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.
Funding Source: Stanley Medical Research Institute
IRB Docket# H00004119